George Pantziarka TP53 Trust – Newsletter LFS UK 2024 Our eighth annual national conference, was held this year on Saturday September 14th at ISH (International Student House) in central London. Responses so far have been really positive, and we are … Read More
The MILI trial is designed to test whether metformin, a drug that treats type II diabetes, can reduce the risk of cancer in people with Li Fraumeni Syndrome (LFS). The truth is that we don’t know if it will or … Read More
Newsletter #6 George Pantziarka TP53 Trust – Newsletter A muddy day out We begin this quarter’s newsletter with a big thank you to Katie Cole-Fallon who, along with her team, have raised £347 for charity. The group spent a sunny … Read More
A lack of access to the recommended screening, particularly annual whole-body (WBMRI) and brain MRI, is the number one issue facing the LFS community in the UK. Currently provision is a hit and miss affair that depends on where you … Read More
George Pantziarka TP53 Trust – Newsletter LFS Awareness Day The George Pantziarka TP53 Trust was once again happy to mark LFS Awareness Day by wearing blue on March 20th. Take a look at Trust Ambassador Patricia Walsh’s outfit this year … Read More
We do not know how many people with Li Fraumeni Syndrome (LFS) there are in the UK. However, as of July 25th 2023, we do know that there are 9,030 people in the UK with Lynch Syndrome, another cancer predisposition … Read More
Newsletter #4 George Pantziarka TP53 Trust – Newsletter We wish all of our friends, families and supporters a very Happy New Year! Liquid Biopsies Early cancer detection is the primary aim in the management of Li Fraumeni Syndrome – early … Read More
Early cancer detection is the primary aim in the management of Li Fraumeni Syndrome – early detection is key to successful cancer treatment. Currently the main mechanisms for this early detection are regular surveillance using whole-body MRI (WBMRI), physical checkups … Read More
Survey now closed.